Mepolizumab shows real-world benefits in patients with severe eosinophilic asthma and CRSwNP: The post-hoc analysis of REALITI-A

Dupilumab demonstrates long-term safety and efficacy among children with type 2 asthma: The EXCURSION study

Demonstrated efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years with HAE: The SPRING study

Real-world effectiveness of benralizumab insevere EOS asthma: The interim integratedanalysis from the XALOC-2 study

Short- and long-term asthma exacerbation risk predicted by AIRQ® score in patients with very poorly controlled disease

Pediatric asthma risk score: A new robust metric for predicting asthma in children